Artivion, Inc.
Financials
Valuation Metrics
Artivion, Inc.'s Market Cap is $1.15B. At end of 2025 it was $2.17B. Ranked #2352 of 3,116 in US market (top 75%), #1404 of 1,644 on NYSE (top 85%), #152 of 203 in Health Care Equipment & Services (top 75%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.15B | US#2,352/3,116 Sec#152/203 |
| Revenue | $471M | US#2,259/3,116 Sec#142/203 |
| Net Income | $-3M | US—/3,116 Sec—/203 |
| Total Assets | $1.07B | US#2,442/3,116 Sec#128/203 |
| Net Assets | $446M | US#2,294/3,116 Sec#122/203 |
| Employees | 1,800 | US#1,735/3,116 Sec#119/203 |
| Value | ||
| P/B | 2.57x | US#1,567/3,116 Sec#76/203 |
| P/S | 2.43x | US#1,463/3,116 Sec#101/203 |
| EV/EBITDA | 25.71x | US#2,099/3,116 Sec#101/203 |
| FCF Yield | -0.95% | US—/3,116 Sec—/203 |
| Profitability | ||
| ROE | -0.71% | US#2,143/3,116 Sec#114/203 |
| ROA | -0.30% | US#2,251/3,116 Sec#120/203 |
| Op. Margin | 4.00% | US#2,054/3,116 Sec#113/203 |
| Revenue Growth | 16.40% | US#825/3,116 Sec#57/203 |
| Financial Health | ||
| Debt Ratio | 140.57% | US#1,422/3,116 Sec#130/203 |
| Total Debt | $408M | US#1,967/3,116 Sec#104/203 |
| FCF | $-11M | US#2,372/3,116 Sec#153/203 |
| Cash | $77M | US#2,361/3,116 Sec#147/203 |
| Current Ratio | 3.47x | US#648/3,116 Sec#65/203 |
| Net Debt/EBITDA | 5.76x | US#2,121/3,116 Sec#131/203 |
| Performance | ||
| 1Y Return | -48.01% | US#2,858/3,116 Sec#185/203 |
| 1M Return | 5.74% | US#1,593/3,116 Sec#141/203 |
| From 52W High | -51.11% | US#2,696/3,116 Sec#182/203 |
| 1Y MDD | -57.80% | US#2,678/3,116 Sec#166/203 |
| Trading | ||
| Volume | 487,677 shares | US#2,440/3,116 Sec#172/203 |
| Trading Value | $11M | US#2,521/3,116 Sec#161/203 |
| Per Share | ||
| EPS | $-0.07 | US—/3,116 Sec—/203 |
| BPS | $9.18 | US#1,894/3,116 Sec#111/203 |
Company Info
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.